Collaborative Science to End ALS Continues with Answer ALS Research Project

September 10, 2015

The ALS Association applauds the announcement of a new research project of Answer ALS to further break down barriers through collaborative science with the ultimate goal of ending amyotrophic lateral sclerosis (ALS).

The Association is pleased to have contributed to the development of this initiative, and through generous donations from the ALS Ice Bucket Challenge, awarded funding to many of the partner organizations that have helped fortify the building blocks of this important initiative.

Answer ALS involves Johns Hopkins University’s Robert Packard Center for ALS Research, Cedars-Sinai Medical Center’s Regenerative Medicine Institute and the Massachusetts General Hospital Neurological Clinical Research Institute, National Institute of Neurological Diseases and Stroke (NINDS) and The ALS Association and will combine big data and comprehensive biological analytics to discover the causes of ALS and develop therapies to treat it. The ALS Association will contribute funds for the sequencing of the samples generated and as the program evolves.

“We are pleased to have been a pivotal part of the development of this large initiative and The ALS Association will continue to partner with NINDS, The Packard Center for ALS Research, Team Gleason and ALS Finding a Cure to advance this research project,” commented Lucie Bruijn, Ph.D. MBA, Chief Scientist for The ALS Association.

Last fall, after the public contributed $115 million through the ALS Ice Bucket Challenge, The ALS Association made significant investments in support of this research project, including The New York Genome Center, Cedar Sinai Stem Cell and Motor Neuron Core Facility, The NEALS Biorepository and NeuroBANK. All these initiatives will contribute to work being done through Answer ALS.

Additionally, The ALS Association recently announced its partnership with Biogen, which will closely align with Answer ALS so all the data can contribute to further enhance the research with the ultimate goal of identifying new targets, advancing drug development, improving clinical trial design and more rapidly finding effective treatments in a better defined ALS population.

“We look forward to continued involvement in Answer ALS and to directing additional funding to continue the momentum of this important collaborative initiative,” continued Bruijn.

Read the Press Release.

Powered by Blackbaud
nonprofit software